Real-world outcomes of prostate-specific membrane antigen-targeted radioligand therapy in Japanese patients with metastatic castration-resistant prostate cancer
PSMA RLT provided meaningful clinical benefit with favorable tolerability in Japanese patients with mCRPC, especially those without prior chemotherapy. Early integration of PSMA RLT may offer additional therapeutic advantages.
Authors
- Chieko Okazaki
- Hidetoshi Kuruma
- Yuki Enei (ORCID: https://orcid.org/0009-0006-1124-2322)
- Takafumi Yanagisawa (ORCID: https://orcid.org/0000-0002-7410-0712)
- Kenta Miki
- Takahiro Kimura (ORCID: https://orcid.org/0000-0002-5673-1553)
- Nat Lenzo (ORCID: https://orcid.org/0000-0003-4882-8766)
- Ken Watanabe (ORCID: https://orcid.org/0000-0002-4328-5662)
- Atsuya Okada
Institutions
- Jikei University School of Medicine (JP)
- Toyonaka Municipal Hospital (JP)
- Theranostics (New Zealand) (NZ)
- Yokohama City University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1093/jjco/hyaf179
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jikei University School of Medicine